Background: As most patients with retroperitoneal sarcomas (RPS) die of local recurrence, front-line aggressive surgery (FAS) has been developed, and it seems to achieve better local control. The aim of this study was to evaluate conformal postoperative radiotherapy (PORT) in patients who had enlarged surgery. Between 1994 and 2008, 110 patients with primary RPS mainly operated by FAS were analysed. Sixty-two patients underwent surgery and no PORT (group S), and 48 received surgery and PORT (group S + R). The median age was 52. Most patients had 3D conformal PORT (81%) with a median dose of 50 Gy.
for distant recurrence, there is no level-1 evidence to suggest that adjuvant chemotherapy mitigates this risk in SRP. As opposed to limb sarcoma, adjuvant radiotherapy (RT) in RPS is not considered a standard, since no randomized trial has addressed the question of surgery combined with adjuvant RT, compared with surgery alone [7] . Thus, decisions for every individual patient are based on results of retrospective studies. In a multi-institutional study where surgery for RPS was 'classical' (limited to the tumour only), adjuvant postoperative RT (PORT) reduced the risk of local relapse by a factor of 3 [2] . More recently, front-line aggressive surgery (FAS), removing non-involved adjacent organs in one bloc with the tumour to optimize margins, has been advocated by surgeons from high-volume centres [8] . This compartmental resection seems to achieve better local control in two retrospective studies [9, 10] . In our team, FAS has been carried out since 1994. Meanwhile, the question of additional benefit on local control of RT after FAS is still open. Thus, we decided to undertake a retrospective evaluation on the role of conformal PORT in RPS patients who had enlarged surgery.
materials and methods
The aim of this study was to determine whether PORT reduced the local relapse rate (LRR) after FAS, based on a retrospective analysis of patients with non-metastatic primary RPS who underwent surgery at Institut Gustave Roussy between 1994 and 2008. Patients were all older than 18, with a performance status between 0 and 2, and were operated for a primary tumour or underwent an early re-excision in case of inappropriate surgery. The diagnosis was confirmed by histological examination of the tumour specimen by an expert pathologist. Sarcomas were classified as (i) low-, (ii) intermediate-or (iii) high-grade lesions according to the French Cancer Centres' histological grading system [11] . Patients who were considered marginally resectable because of their size or location were discussed within a multidisplinary setting to receive neoadjuvant treatment consisting generally of an anthracycline-based regimen (adriamycin and iphosphamide). The R classification of International Union Against Cancer was used to describe the quality of resection [12] . All sarcoma patients are seen systematically postoperatively, in our multidisciplinary meeting, with the complete surgical and pathological report to discuss adjuvant treatments. Thus, we included only patients for whom PORT was discussed in a collegial manner within 4-6 weeks after surgery. It should be outlined that most patients for whom RT was considered, because of a higher risk of recurrence (R1 resections, higher grade tumours), had omentoplasty or expanders to displace small bowel from the tumour bed during the surgical procedure. Toxicity was graded according to Common Terminology Criteria for Adverse Events version 3.0 (CTCAE-V3). It should be mentioned that there is a certain ambiguity regarding LRR as local failures can be localized (local relapse) or plurifocal within the abdomen, and we then describe them as sarcomatosis. Thus, we have chosen the term of abdominal relapse rather than local relapse, as in many studies. The abdominal relapse rate (ARR) was defined as the time between the date of surgery or the last surgery in case of re-excision and the date of the first local recurrence within the abdomen. Recurrence-free survival (RFS) was defined as the time from surgery to the first recurrence (abdominalor distant) or death, whichever occurred first. Patients alive without recurrence were censored at the date of the last follow-up. The distant metastasis-free survival was defined as the time from surgery to the first distant metastatic recurrence or death. Patients alive without abdominal and/or metastatic recurrence were censored at the date of the last followup. Overall survival was defined as the time from surgery to death, whatever the cause. Patients who remained alive were censored at the date of the last follow-up.
Thus, we decided to compare patients who had PORT (S + R) with patients who had no PORT (S). Patients' characteristics in the two groups were compared using chi-square test or Fisher's exact test for categorical variables and Student's t-test for continuous variables. The abdominal control rate, RFS, distant metastases-free survival and overall survival were estimated using the Kaplan-Meier method [13] . The hazard ratios of an event (death, recurrence) with surgery plus RT compared with surgery were computed using a multivariate Cox model adjusted on the following covariates: surgical resection margins: R0 versus R1, R2; tumour grade; tumour size: ≤10, >10 cm; age: ≤60 years, >60 years; administration of chemotherapy and histology: liposarcoma versus other histologies. The median follow-up was calculated using the inverted Kaplan-Meier method. For abdominal relapse, RFS, metastasis-free survival and overall survival, an adjusted hazard ratio was calculated, taking into account surgical resection margins, tumour grade, tumour size, age, chemotherapy and histology.
results
Overall, 119 patients, 55 men and 64 women, have been operated between November 1994 and November 2008. Nine patients were excluded from the analysis, as PORT could not be discussed and considered in the multidisplinary meeting: five due to early treatment-related death, two due to metastatic disease found at the time of surgery and for two patients, because there was no follow-up data after surgery. So the mortality rate within the first 30 days after surgery was 4%: the complications that led to death were fistula and iliac artery rupture in two patients, hemoperitoneum in one patient, severe sepsis in one patient and air embolism in one patient. Therefore, the analysis is based on 110 patients. Among these 110 patients, 62 underwent surgery and no PORT (group S) and 48 received RT after surgery (group S + R).
The patients' characteristics are described in Table 1 , and treatment characteristics in Table 2 . The median age was 54 (range 19-77) in group S and 50 (range 21-80) in group S + R. The large majority of patients (N = 103, 94%) had FAS technique, as previously described [8] . Liposarcoma was the most common histological type representing 60% of the patients (Table 2) . Leiomyosarcoma was the second most important type with 14% of the patients. The median size of resected tumours was 25 cm among assessable patients ( primary resection with no previous treatment). Most patients presented a grade-1 tumour (42%). Among the 12 patients reoperated after an inadequate resection, residual tumour was found in 8 patients (66%). Unfavourable prognostic factors were significantly more frequently identified in the S + R group, as a result of the decision making of our multidisciplinary team. RT (group S + R) was administered more frequently in patients with R1 and R2 margins (P = 0.03) or grade-3 tumours (40% versus 24%). As described in Table 2 , 41 patients (37%) received a neoadjuvant treatment before surgery consisting of chemotherapy; most patients had stable disease or partial response. The median percentage of residual cells among the 33 pathologically assessable patients was 48% (3%-100%) in the group of 10 patients who had no PORT versus 40% in the group of 23 patients who had PORT (P = 0.93). Considering that neoadjuvant treatment might have had an impact on the outcome, we analysed it. There was no significant difference in terms of survival (P = 0.19), whether patients had neoadjuvant treatment consisting of chemotherapy (respectively, 80% and 73% at 2 and 5 years) or not (92% and 76%). Nevertheless, this item was included in the multivariate analysis. There were significantly more patients receiving such treatment in group S + R (58% versus 21%, P < 0.0001). There were more liposarcomas in group S (68% versus 46%, P = 0.03) and more patients with grade-1 tumours (50% versus 31%), although this difference was not statistically significant (P = 0.11).
Forty-eight patients received PORT. The median postoperative dose was 50.40 in 1.8 Gy fractions (range 14-62). Fourteen patients had a boost to the region at higher risk of failure at a median dose of 15.5 Gy (range 9-20). Most patients had conformal RT (81%). Among patients who had PORT, 11 patients (23%) had a moderate acute intestinal toxicity (<grade 3) and 9 patients (19%) experienced a late intestinal toxicity: 1 had to be operated for small-bowel obstruction (grade 3), 2 patients had a sub-occlusive episode that spontaneously resolved (grade 1) and 6 patients complained of moderate diarrhoea (grade 1). Thus, only one patient required surgical intervention.
The median follow-up is 4.1 years (4.9 years in group S + R and 3.8 years in group S). Local recurrence was recorded for 19 patients, 6 in group S + R and 13 in group S. The cumulative rates of local failure as well as the survival curves are shown in Figures 1 and 2 and supplementary Figure S1 , available at Annals of Oncology online. Median local-relapse free survival was not assessable because there was <50% of local relapse in both groups. The cumulative rate of abdominal relapse at 2 and 5 years was, respectively, 6% and 22% in the S + R group and 12% and 36% in the S group. The adjusted hazard ratio of original articles Annals of Oncology abdominal relapse is 0.48 (95% CI: 0.16-1.39, P = 0.18). The RFS rate at 2 and 5 years was, respectively, 80% and 60% in the S + R group and 79% and 47% in the S group. The adjusted hazard ratio of recurrence is 0.43 (95% CI: 0.20-0.88, P = 0.02). Overall, 27 patients had a distant recurrence, 14 in the S + R group and 13 in the S group. Median distant RFS is 7.8 years in the S + R group and is not reached in the S group (meaning that <50% of patients have a metastatic recurrence in group S). The adjusted hazard ratio of distant recurrence is 0.79 (95% CI: 0.33-1.90, P = 0.60). Overall, 23 patients died: 13 in group S + R and 10 in group S. Median overall survival is 10 years in the group S + R and is not reached in the S group. The adjusted hazard ratio of death with S + R versus S is 0.91 (95% CI: 0.34-1.39, P = 0.84). We analysed the 19 patients who had a local relapse within the abdomen (abdominal relapse) as shown in Figures 3 and 4 in supplementary Table S1 , available at Annals of Oncology online. Among them, seven could receive surgery with adjuvant RT and/or CT and are free of disease. All the other patients who could not be operated died of abdominal progression.
discussion
In our retrospective single-institution study, the large majority of patients (94%) had FAS. We analysed our population considering the fact that they had or not PORT. Consistent with other recent retrospective studies [9, 10, 14, 15] , our results suggest that adjuvant RT could be beneficial in terms of local control and RFS in primary RPS, even after extensive surgery. With an actuarial survival rate in the whole population of 76% at 5 years (95% CI: 65%-84%), we found a better overall survival compared with most retrospective studies where 5-year survival rates generally do not exceed 55% [2] [3] [4] [5] . Local recurrence was the predominant form of relapse for low and intermediate grades (but was lower than usually reported) [2-4, 16, 17] , with a cumulative rate of local relapse at 5 years of 30% (range 19%-42%). Similar improvement of both OS and local control was found in the recent Gronchi et al. study [18] (5-year OS 68.2% and 5-year LRR 20.7% for primary tumours when compared with historical data). The achievement of better outcome could be explained by the addition of more aggressive surgical approaches such as FAS, the implementation of modern conformal RT and optimization of combined modality treatment [9, 10, 19] . Concerning surgery, the two first studies [9, 10] exploring the possible impact of a more aggressive surgical approach report local recurrence rates of 30%, whereas in previous studies, after a simple excision of the tumour eventually combined with the surrounding viscera directly involved, the rate of abdominal recurrence is ∼50% at 5 years [2-4, 16, 17] . In the Bonvalot et al. multi-institutional study [9] , independent predictive factors associated with a better local control were low grade, FAS and a larger number of patients undergoing surgery per centre. The 3-year abdominal recurrence rate was 10% for FAS compared with 47% for simple resection. In Gronchi et al.'s study [10] , the 5-year rate of local recurrences for patients who underwent simple excision in the early period was 48% (95% CI: 40%-57%), whereas it was 29% (95% CI: 20%-37%) for patients treated with FAS in the recent period. These initial published results are now supported by their recent updates [18, 20] . The 30% local recurrence rate (LRR) at 5 years observed in our patients seems to be consistent and compares favourably with previously published studies recently collected in a systematic review [19] . Among patients who had a local failure during the follow-up, only those who could undergo re-excision are free of disease. Multiple local resections can be offered in low-grade RPS, and justify a rigorous surgical follow-up. All these results comfort a more aggressive surgical approach, which may significantly improve the patients' outcome.
Concerning RT, previous studies have shown that RT could improve local control but at the cost of increased intestinal toxicity, limiting its indications especially at the era of 2D RT [19, 21] . The delivery of postoperative doses over 50 Gy was hampered by the presence of small bowel in the tumour bed, so the risk of acute and chronic radiation enteritis has been reported in up to 50% of patients in old series [22] . As smallbowel toxicity is correlated with the delivered dose but also with the irradiated volume [23] , patients with large RPS are particularly at risk. Thus, it is of no surprise that in epidemiological data studies, only 25% of patients undergo RT [1, 14, 15] . In our patients, gastrointestinal toxic effects seem low compared with those reported with 2D postoperative radiation. With >80% of patients having 3D RT, only one grade-3 bowel toxicity was observed (2%). Several methods have been proposed to displace the bowel outside the radiation field [24] , and omentoplasty or tissue expanders were used in most of our patients. The use of newer radiation delivery techniques such as intensity-modulated radiation therapy may also reduce the dose delivered to the small bowel, thereby reducing toxicity [25] [26] [27] [28] .
The further question is: can we do better with the addition of modern RT to the FAS? In the two initial studies and their update [9, 10, 18, 20] , adjuvant RT seems to have a beneficial impact on local control in all operated patients, with or without FAS. In Gronchi et al.'s study [10] , the reported crude cumulative incidence of local relapse at 5 years was 32% after such surgery alone versus 19% after the same surgery and RT. In another recent multi-institutional study, even if 75% of patients had surgery alone, patients who received RT had a lower 5-year LRR of 21% versus 36% without adjuvant RT [14] . However, the benefit of RT was found only in patients who had conservative surgery consisting of local removal of the tumour only, while no benefit was found for patients who had wider resection with other organs. In our study, where 94% patients had FAS, we cannot conclude that RT has an impact on local control, as the results were statistically not significant. However, LRR at 5 years was 36% in patients who had no PORT despite better prognostic factors in this group and 22% in patients who had PORT. We can highlight several arguments for these non-significant studies: few events observed during the follow-up and mainly, the retrospective design where patients allocated to PORT presented worse characteristics considering histology, grade and resection margins. Thus, it seems RT could provide clinical benefit to patients with poor prognostic clinical factors. The question of adjuvant RT is still controversial as pointed out by the recently published Surveillance, Epidemiology, and End Results (SEER) data-based study whose objective was to determine the effect of radiation therapy on disease-specific and overall survival. The study which included 762 surgically resected RPS patients (204 patients in group S + R compared with 558 patients in group S) could not show any beneficial role of RT either on DFS or on OS [29] . It should be outlined that, as it is a SEER data-based study, the quality of surgery is not detailed ( partial/simple surgery as opposed to radical/total surgery) and no information regarding the quality of RT in terms of dose, technique and toxicity is given. As in our study, patients who received RT tended to have more advanced stage and higher grade and more aggressive tumours. Even after a propensity score-adjusted analysis, so as to balance the baseline covariates in the two groups, the authors conclude that only a randomized trial may assess the impact of RT on survival.
As more aggressive surgical approaches have been implemented to achieve better local control [8] , it becomes of outmost importance to confirm prospectively whether adjuvant RT should be administered to these patients. As in limb sarcoma, there has been a large interest in preoperative RT. Several studies have reported promising results with preoperative conformal RT in RPS, but the quality of surgical resection is seldom described [16, 24, 27, 28, [30] [31] [32] . In the update of two prospective studies, 75% of patients who underwent preoperative RT had a complete resection [16, 31, 32] . Among the 72 patients with high-grade RPS included, the 2-and 5-year local RFS rates were, respectively, 79% and 60%, and the 5-year OS rate was 61% [16] . These data compare favourably with historical controls, especially considering that 75% of patients had primary tumours and 25% had recurrent RPS. Furthermore, preoperative radiation being administered with the tumour in situ allows the tumour to displace original articles Annals of Oncology radiosensitive viscera such as bowel out of the radiation treatment volume, so RT can be administered with relatively little risk of injury to adjacent normal tissues [16, 19, 27, 28, [30] [31] [32] . When severe toxicity was observed, it was more frequently related to intraoperative RT or brachytherapy, which was delivered after preoperative RT in certain studies as a boost [16, 19, [30] [31] [32] . Several advantages have been highlighted in the recent literature in favour of preoperative conformal RT: easier and more reproducible tumour volume delineation and accurate treatment planning; organs at risk, particularly radiosensitive, such as small bowel are displaced outside treatment field; fewer surgical adhesions; biologically effective radiation dose lower in preoperative setting; risk of potential contamination of the abdomen during surgery. This approach needs to be evaluated in a prospective study, combined with a translational research study to better understand the biology of such tumours. Therefore, a phase III, randomized, multiinstitutional EORTC study (European Organisation for Research and Treatment of Cancer, EORTC 62092-22092) comparing preoperative conformal RT with or without intensity modulation followed by surgery with surgery alone is open and will hopefully contribute to establish the role of RT.
